Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

Akari Therapeutics Plc: Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...
Morning Overview on MSN

1 mitochondrial protein may be the key to longer, healthier living

Longevity science has spent decades chasing single molecules that might slow aging, but most candidates have delivered modest ...